It’s only fair to share… Florensocatib CAS 2762114-61-2 MF C23H23FN4O4 MW438.5 g/mol (2S)-N-[(1S)-1-cyano-2-[2-fluoro-4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide (2S)-N-{(1S)-1-cyano-2-[2-fluoro-4-(3-methyl-2-oxo-2,3-dihydro1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamidecathepsin inhibitor, HSK 31858, CHF 10196, DPP1-IN-1, RWC743JRK7 Florensocatib (originally designated as HSK31858 or CHF10196) is an investigative, highly potent, oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being actively researched for its ability to reduce the frequency of pulmonary exacerbations …
Category «Uncategorized»
Florcicaper (18F)
It’s only fair to share… Florcicaper (18F) CAS 855927-17-2 MF C18H3318FO2, MW 299.4544 2-[(1S,2R)-2-(5-(18F)fluorotridecyl)cyclopropyl]acetic acid 2-((1S,2R)-2-(5-(FLUORO-18F)TRIDECYL)CYCLOPROPYL)ACETIC ACID TRANS-9(RS)-18F-FLUORO-3,4(RS,RS)-METHYLENEHEPTADECANOIC ACID rac-{(1R,2S)-2-[(5RS)-5-(18F)fluorotridecyl]cyclopropyl}aceticacidimaging agent, CARDIOPET, (18F FCPHA), FDG79C95XB CardioPET is: An F-18 labeled, modified fatty acid that provides insight into regions with decreased blood flow or metabolic insufficiency in the myocardium.; CardioPET may be used to: Identify patients …
Fexlamose
It’s only fair to share… Fexlamose CAS 1285607-08-0 MFC12H22O9S2 MW374.4 g/mol (2S,3S,4S,5R,6R)-2-(sulfanylmethyl)-6-[(2R,3R,4S,5S,6S)-3,4,5-trihydroxy-6-(sulfanylmethyl)oxan-2-yl]oxyoxane-3,4,5-triol 6-thio-α-D-glucopyranosyl 6-thio-α-D-glucopyranoside; 6,6′-dithiotrehalosemucolytic, AER-01, AER 01, VY9GAK6EVR, MUC-031, MUC031 Fexlamose (formerly known as AER-01) is an experimental inhaled small-molecule drug developed by Aer Therapeutics to treat muco-obstructive lung diseases like COPD (Chronic Obstructive Pulmonary Disease) and asthma. It is a thiol-modified carbohydrate designed to …
Famlasertib
It’s only fair to share… Famlasertib CAS 2375591-69-6 MFC26H27ClN4O MW 447.0 g/mol 4-[[4-[3-(3-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-1-piperazineethanol 2-[4-({4-[3-(3-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl}methyl)piperazin-1-yl]ethan-1-olserine/threonine kinase inhibitor, amyotrophic lateral sclerosis, Prosetin, WJP32276AY Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis. Famlasertib (also known as Prosetin or Prostetin/12k) is a highly potent, small-molecule inhibitor targeting the mitogen-activated protein kinase …
Epaldeudomide
It’s only fair to share… Epaldeudomide CAS 1918159-31-5 MF C25H252HFN3O5, MW 468.5 g/mol (3S)-3-deuterio-3-[7-[[2-fluoro-4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione (3S)-3-[4-[[2-Fluoro-4-(4-morpholinylmethyl)phenyl]methoxy]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-2,6-piperidinedione-3-d KPG-818, KPG 818, ANTINEOPLASTIC, KV0TBL8MUS Epaldeudomide (also known as KPG-818) is an investigational, next-generation immunomodulatory drug and “molecular glue” developed by Kangpu Biopharmaceuticals. Designed as a targeted therapy, it works by binding to the CRL4-CRBN E3 ubiquitin ligase complex to degrade …
Enozertinib
It’s only fair to share… Enozertinib CAS 2489185-38-6 MF C35H42F2N8O3 MW660.8 N-[2-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-5-[[6-[(3R)-3-(3,5-difluorophenyl)-1,2-oxazolidin-2-yl]pyrimidin-4-yl]amino]-4-methoxyphenyl]prop-2-enamide epidermal growth factor receptor tyrosine kinase inhibitor, antineoplastic, ORIC-114, ORIC 114, DU24UP8R94 Enozertinib (formerly ORIC-114) is an investigational, orally bioavailable, and brain-penetrant dual EGFR/HER2 inhibitor developed by ORIC Pharmaceuticals. It targets cancers with exon 20 insertion and atypical EGFR mutations. Its core profile …
Engasertib
It’s only fair to share… Engasertib CAS 1313439-71-2 MF C25H25N3O3 MW415.5 g/mol 1H-Pyrido[2,3-b][1,4]oxazin-2(3H)-one, 6-[4-(cis-1-amino-3-hydroxycyclobutyl)phenyl]-1-ethyl-7-phenyl- 6-[4-(1-amino-3-hydroxycyclobutyl)phenyl]-1-ethyl-7-phenylpyrido[2,3-b][1,4]oxazin-2-one 6-{4-[(1S,3S)-1-amino-3-hydroxycyclobutyl]phenyl}-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-oneserine/threonine kinase inhibitor, ALM-301, VAD-044, ALM 301, VAD 044, Orphan Drug, K2US8HW4TQ Engasertib is an oral, once-daily AKT inhibitor developed by Vaderis Therapeutics, primarily investigated as a targeted therapy for Hereditary Hemorrhagic Telangiectasia (HHT). Clinical trials show it safely reduces the …
Encofosbuvir
It’s only fair to share… Encofosbuvir, Yiqibuvir CAS 2232134-77-7 MF C30H42FN4O13PS MW 748.7 g/mol [3-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-3-methyl-5-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-2-yl]-2,6-dioxopyrimidin-1-yl]methyl (2S)-2-(methoxycarbonylamino)-4-methylsulfanylbutanoate antiviral, HEC 110114; Yiqibuvir, CHINA 2025, APPROVALS 2025, 82E4Q8WQV7 Encofosbuvir is a novel, oral small-molecule direct-acting antiviral (DAA) drug used to treat the hepatitis C virus (HCV). Approved by China’s National Medical Products Administration (NMPA) in March 2025, it serves …
Emupertinib
It’s only fair to share… Emupertinib CAS 2472802-77-8 MFC30H26N8O MW514.6 g/mol 2-Pyrazinecarboxamide, N-[4-[4-amino-6-ethynyl-5-(3-quinolinyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]bicyclo[2.2.1]hept-1-yl]-5-methyl- N-{4-[4-amino-6-ethynyl-5-(quinolin-3-yl)-7Hpyrrolo[2,3-d]pyrimidin-7-yl]bicyclo[2.2.1]heptan-1-yl}-5-methylpyrazine-2-carboxamideepidermal growth factor receptor tyrosine kinase, inhibitor, antineoplastic, TAS3351, TAS 3351, CU9YW8A5TP Emupertinib is a potent, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It possesses selective antineoplastic potential for targeting specific mutant profiles of cancer cells. The compound was originally …
Sonrotoclax
It’s only fair to share… Sonrotoclax CAS 2383086-06-2 MW 890.1 g/mol, MFC49H59N7O7S FDA APPROVED 5/13/2026, Beqalzi, APPROVALS 2026, BGB-11417, BGB 11417, 30R67U9KYS N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[2-[(2S)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective …